The Use of Aromatase Inhibitors in Boys with Short Stature: What to Know Before Prescribing?

Overview

Journal Arch Endocrinol Metab

Specialty Endocrinology

Date 2017 Oct 5

PMID 28977209

Citations 9

Authors

Alessandra Linardi

Durval Damiani

Carlos A Longui

Affiliations

Soon will be listed here.

Abstract

Aromatase is a cytochrome P450 enzyme (CYP19A1 isoform) able to catalyze the conversion of androgens to estrogens. The aromatase gene mutations highlighted the action of estrogen as one of the main regulators of bone maturation and closure of bone plate. The use of aromatase inhibitors (AI) in boys with short stature has showed its capability to improve the predicted final height. Anastrozole (ANZ) and letrozole (LTZ) are nonsteroidal inhibitors able to bind reversibly to the heme group of cytochrome P450. In this review, we describe the pharmacokinetic profile of both drugs, discussing possible drug interactions between ANZ and LTZ with other drugs. AIs are triazolic compounds that can induce or suppress cytochrome P450 enzymes, interfering with metabolism of other compounds. Hydroxilation, N-dealkylation and glucoronidation are involved in the metabolism of AIs. Drug interactions can occur with azole antifungals, such as ketoconazole, by inhibiting CYP3A4 and by reducing the clearance of AIs. Antiepileptic drugs (lamotrigine, phenobarbital, and phenytoin) also inhibit aromatase. Concomitant use of phenobarbital or valproate has a synergistic effect on aromatase inhibition. Therefore, it is important to understand the pharmacokinetics of AIs, recognizing and avoiding possible drug interactions and offering a safer prescription profile of this class of aromatase inhibitors. Arch Endocrinol Metab. 2017;61(3):391-7.

Citing Articles

Aromatase inhibitors: a useful additional therapeutic option for slowing down advanced bone age in boys with growth hormone deficiency.

Akin Kagizmanli G, Ozalp Kizilay D, Besci O, Yuksek Acinikli K, Ozen S, Demir K J Endocrinol Invest. 2023; 47(5):1227-1235.

PMID: 38040920 DOI: 10.1007/s40618-023-02242-w.

Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs.

Deb S, Hopefl R Daru. 2023; 31(2):95-105.

PMID: 37223851 PMC: 10624783. DOI: 10.1007/s40199-023-00463-1.

Pyridine based dual binding site aromatase (CYP19A1) inhibitors.

Eissa A, Powell L, Gee J, Foster P, Simons C RSC Med Chem. 2023; 14(2):356-366.

PMID: 36846364 PMC: 9945863. DOI: 10.1039/d2md00352j.

Palbociclib-induced severe hepatitis: A case study and literature review.

Hyppolite J, Hilzenrat N Can Liver J. 2022; 4(4):433-437.

PMID: 35989889 PMC: 9235127. DOI: 10.3138/canlivj-2021-0015.

Development of sheep secondary follicles and preservation of aromatase and metalloproteinases 2 and 9 after vitrification and in vitro culture.

Gomes F, de Brito D, de Sa N, Naupas L, Palomino G, da Silva R Cell Tissue Bank. 2021; 23(2):247-259.

PMID: 34152507 DOI: 10.1007/s10561-021-09937-5.

References

YATES R, Wong J, Seiberling M, Merz M, Marz W, Nauck M . The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol. 2001; 51(5):429-35. PMC: 2014464. DOI: 10.1046/j.1365-2125.2001.01358.x. View

Turkistani A, Marsh S . Pharmacogenomics of third-generation aromatase inhibitors. Expert Opin Pharmacother. 2012; 13(9):1299-307. DOI: 10.1517/14656566.2012.687721. View

Niwa T, Imagawa Y, Yamazaki H . Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. Curr Drug Metab. 2014; 15(7):651-79. DOI: 10.2174/1389200215666141125121511. View

Grimm S, Dyroff M . Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos. 1997; 25(5):598-602. View

Trosken E, Fischer K, Volkel W, Lutz W . Inhibition of human CYP19 by azoles used as antifungal agents and aromatase inhibitors, using a new LC-MS/MS method for the analysis of estradiol product formation. Toxicology. 2005; 219(1-3):33-40. DOI: 10.1016/j.tox.2005.10.020. View

Murai K, Yamazaki H, Nakagawa K, Kawai R, Kamataki T . Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica. 2009; 39(11):795-802. DOI: 10.3109/00498250903171395. View

Boeddinghaus I, Dowsett M . Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. J Steroid Biochem Mol Biol. 2002; 79(1-5):85-91. DOI: 10.1016/s0960-0760(01)00126-1. View

McGrath N, OGrady M . Aromatase inhibitors for short stature in male children and adolescents. Cochrane Database Syst Rev. 2015; (10):CD010888. PMC: 9251633. DOI: 10.1002/14651858.CD010888.pub2. View

Denton T, Zhang X, Cashman J . Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. Biochem Pharmacol. 2004; 67(4):751-6. DOI: 10.1016/j.bcp.2003.10.022. View

10.

Ehmer U, Vogel A, Schutte J, Krone B, Manns M, Strassburg C . Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology. 2004; 39(4):970-7. DOI: 10.1002/hep.20131. View

11.

Juul A, Bang P, Hertel N, Main K, Dalgaard P, Jorgensen K . Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab. 1994; 78(3):744-52. DOI: 10.1210/jcem.78.3.8126152. View

12.

Mauras N . Strategies for maximizing growth in puberty in children with short stature. Pediatr Clin North Am. 2011; 58(5):1167-79, x. DOI: 10.1016/j.pcl.2011.07.007. View

13.

Lonning P, Pfister C, Martoni A, Zamagni C . Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol. 2003; 30(4 Suppl 14):23-32. DOI: 10.1016/s0093-7754(03)00305-1. View

14.

Rochira V, Zirilli L, Maffei L, Premrou V, Aranda C, Baldi M . Tall stature without growth hormone: four male patients with aromatase deficiency. J Clin Endocrinol Metab. 2010; 95(4):1626-33. DOI: 10.1210/jc.2009-1743. View

15.

Shufelt C, Merz C, Yang Y, Kirschner J, Polk D, Stanczyk F . Red versus white wine as a nutritional aromatase inhibitor in premenopausal women: a pilot study. J Womens Health (Larchmt). 2011; 21(3):281-4. PMC: 3298670. DOI: 10.1089/jwh.2011.3001. View

16.

Sata F, Sapone A, Elizondo G, Stocker P, Miller V, Zheng W . CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther. 2000; 67(1):48-56. DOI: 10.1067/mcp.2000.104391. View

17.

Zanger U, Schwab M . Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138(1):103-41. DOI: 10.1016/j.pharmthera.2012.12.007. View

18.

Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J . Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med. 1997; 337(2):91-5. DOI: 10.1056/NEJM199707103370204. View

19.

Colussi D, Parisot C, Lefevre G . Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor. J Clin Pharmacol. 1998; 38(8):727-35. DOI: 10.1002/j.1552-4604.1998.tb04813.x. View

20.

Desta Z, Kreutz Y, Nguyen A, Li L, Skaar T, Kamdem L . Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther. 2011; 90(5):693-700. PMC: 3667657. DOI: 10.1038/clpt.2011.174. View